Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Daniela Ramos
Institution:
Baylor College of Medicine
Observed institution:
Baylor College of Medicine
ORCID:
0000-0002-8940-0232
Observed ORCIDs:
0000-0002-8940-0232,
0000-0002-3848-6478
OpenAlex ID:
A5008477330
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
2022
·
Hyun-Sung Lee
, Hee-Jin Jang
, et al.
·
Clinical Cancer Research
·
53
PDF
Transcriptome-based molecular subtyping of non–small cell lung cancer may predict response to immune checkpoint inhibitors
2019
·
Hee-Jin Jang
, Hyun-Sung Lee
, et al.
·
Journal of Thoracic and Cardiovascular Surgery
·
40
PDF
Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma
2021
·
Hee-Jin Jang
, Cynthia Y. Truong
, et al.
·
The Annals of Thoracic Surgery
·
33
PDF
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment
2022
·
Hee-Jin Jang
, Hyun-Sung Lee
, et al.
·
Cancer Research
·
20
PDF
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma
2020
·
Hyun-Sung Lee
, Masatsugu Hamaji
, et al.
·
The Annals of Thoracic Surgery
·
9
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1 -Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
·
Cancer Research
·
3
Data from A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma
2023
·
Hyun-Sung Lee
, Hee-Jin Jang
, et al.
·
2
Supplemental Figure 3 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 6 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 11 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 17 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 7 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Data from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 4 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 13 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 5 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 9 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 12 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 3 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 10 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 8 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 1 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 7 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Show more works
View as search
Works count:
87
Citation count:
160
H-index:
5
I10-index:
4
Year
Topic
Type